Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that management will participate at both the upcoming KBC Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology.

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that management will participate at both the upcoming KBC Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology.

The KBC Healthcare Conference will take place in New York, NY on September 27, 2018.


The Leerink Partners Roundtable Series: Rare Disease & Oncology will take place in New York, NY on October 2-3, 2018 and the Company is scheduled to present on Wednesday, October 3 at 4:00 p.m. ET.  A live webcast of the presentation can be accessed at http://wsw.com/webcast/leerink31/cyad/. An archived webcast recording will also be available under Events & Webcasts in the Investors section of the Company’s website.

 

***END***

Download press release(s)

Press release

93.58 Ko

Communiqué de presse

96.03 Ko

Persbericht

94.04 Ko

Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications

Next News

Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications